OncoMatch/Clinical Trials/NCT06245746
UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia
Is NCT06245746 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies umbilical cord derived mesenchymal stem cells exosomes (UCMSC-Exo) for acute myeloid leukemia.
Treatment: umbilical cord derived mesenchymal stem cells exosomes (UCMSC-Exo) — The purpose of the study is to explore the safety and efficacy of UCMSC-Exo in consolidation chemotherapy-induced myelosuppression in patients with acute myeloid leukemia after achieving complete remission.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: cytarabine or cytarabine-based consolidation therapy (cytarabine) — consolidation
are going to receive consolidation therapy (cytarabine or cytarabine-based combined regimen, the cycle of consolidation therapy is not limited)
Cannot have received: radiation therapy on sternum or pelvis
Previous radiation therapy performed on sternum or pelvis
Cannot have received: immunosuppressants
Continuous usage of immunosuppressants or received organ transplantation in the last 6 months
Cannot have received: clinical trial drugs
Participation in clinical trials of other drugs within 6 weeks before enrollment
Cannot have received: clinical stem cell or exosome research
Previous participation in clinical stem cell or exosome research
Cannot have received: agents inhibiting cell division (hydroxyurea, low-dose cytarabine, methotrexate)
Receive any agent concurrently with UCMSC-Exo infusion which inhibits cell division (hydroxyurea, low-dose cytarabine or methotrexate, etc)
Lab requirements
Kidney function
serum creatinine of at most 1.5 times/upper limit of normal value
Liver function
alanine aminotransferase/aspartate aminotransferase of at most 2.5 times/upper limit of normal value and serum total bilirubin of at most 1.5 times/upper limit of normal value
Cardiac function
ejection fraction of left ventricular of at least 45%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06245746 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy on sternum or pelvis, immunosuppressants, clinical trial drugs disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 60 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages